Redox-related antimelanoma activity of ATN-224

Melanoma Research

Volumn 19, Issue 6, 2009, Pages 350-360

  Trapp, Valerie ^a   Lee, Kristy ^a   Doñate, Fernando ^b   Mazar, Andrew P ^b   Fruehauf, John P ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Attenuon LLC   (United States)

Author keywords

Arsenic trioxide; Buthionine sulfoximine; Disulfiram; Melanoma; Reactive oxygen species; Redox; Superoxide dismutase; Temozolomide; Tetrathiomolybdate

Indexed keywords

ARSENIC TRIOXIDE; ATN 224; BUTHIONINE SULFOXIMINE; COPPER ZINC SUPEROXIDE DISMUTASE; DISULFIRAM; GLUTATHIONE; GLUTATHIONE DISULFIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; REACTIVE OXYGEN METABOLITE; TEMOZOLOMIDE; TETRATHIOMOLYBDIC ACID; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL STRAIN MCF 7; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DNA CONTENT; DRUG ANTAGONISM; DRUG POTENTIATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; MELANOMA CELL; OVARY CANCER; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; APOPTOSIS; ARSENICALS; BUTHIONINE SULFOXIMINE; CELL LINE, TUMOR; CELL PROLIFERATION; DACARBAZINE; DISULFIRAM; DRUG SYNERGISM; ENZYME INHIBITORS; GLUTATHIONE; HUMANS; MELANINS; MELANOMA; MOLYBDENUM; OXIDATION-REDUCTION; OXIDES; REACTIVE OXYGEN SPECIES; SUPEROXIDE DISMUTASE;

EID: 73349096278     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/CMR.0b013e32832c6324     Document Type: Article

References (38)

1. Keilholz U. Biochemotherapy of melanoma. Forum 2003; 13:158-165.
2. Chapman PB, Einhorn LH, Meyers ML, Saxman S, Destro AN, Panageas KS, et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 1999; 17:2745-2751.
3. Ives NJ, Stowe RL, Lorigan P, Wheatley K. Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2621 patients. J Clin Oncol 2007; 25:5426-5434.
4. Hancock BW,Wheatley K, Harris S, Ives N, Harrison G, Horsman JM, et al. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study - United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma. J Clin Oncol 2004; 22:53-61.
5. Soengas MS, Lowe SW. Apoptosis and melanoma chemoresistance. Oncogene 2003; 22:3138-3151.
6. Hussein MR, Haemel AK, Wood GS. Apoptosis and melanoma: molecular mechanisms. J Pathol 2003; 199:275-288.
7. Riley PA. Radicals in melanin biochemistry. Ann N Y Acad Sci 1988; 551:111-119.
8. Meyskens FL Jr, McNulty SE, Buckmeier JA, Tohidian NB, Spillane TJ, Kahlon RS, et al. Aberrant redox regulation in human metastatic melanoma cells compared to normal melanocytes. Free Radic Biol Med 2001; 31:799-808.
9. Meyskens FL Jr, Farmer P, Fruehauf JP. Redox regulation in human melanocytes and melanoma. Pigment Cell Res 2001; 14:148-154.
10. Nofsinger JB, Liu Y, Simon JD. Aggregation of eumelanin mitigates photogeneration of reactive oxygen species. Free Radic Biol Med 2002; 32:720-730.
11. Farmer PJ, Gidanian S, Shahandeh B, Di Bilio AJ, Tohidian N, Meyskens FL Jr. Melanin as a target for melanoma chemotherapy: pro-oxidant effect of oxygen and metals on melanoma viability. Pigment Cell Res 2003; 16:273-279.
12. Riley PA. Melanogenesis: A realistic target for antimelanoma therapy? Eur J Cancer 1991; 27:1172-1177.
13. Jimbow K, Iwashina T, Alena F, Yamada K, Pankovich J, Umemura T. Exploitation of pigment biosynthesis pathway as a selective chemotherapeutic approach for malignant melanoma. J Invest Dermatol 1993; 100:231S-238S.
14. Fruehauf JP, Meyskens FL. Reactive oxygen species: a breath of life or death? Clin Can Res 2007; 13:789-794.
15. Serio CD, Doria L, Pellerito S, Prudovsky I, Micucci I, Massi D, et al. The release of fibroblast growth factor-1 from melanoma cells requires copper ions and is mediated by phosphatidylinositol 3-kinase/Akt intracellular signaling pathway. Cancer Lett 2008; 267:67-74.
16. Govindarajan B, Sligh JE, Vincent BJ, Li M, Canter JA, Nickloff BJ, et al. Overexpression of Akt converts radial growth melanoma to vertical growth melanoma. J Clin Invest 2007; 117:719-729.
17. Fruehauf JP, Zonis S, Al-Bassam M, Kyshtoobayeva A, Dasgupta C, Milovanovic T, et al. Selective and synergistic activity of L-S,R-buthionine sulfoximine on malignant melanoma is accompanied by decreased expression of glutathione-S-transferase. Pigment Cell Res 1997; 10:236-249.
18. Zelko IN, Mariani TJ, Folz RJ. Superoxide dismutase multigene family: a comparison of the CuZn-SOD (SOD1), Mn-SOD (SOD2), and EC-SOD (SOD3) gene structures, evolution, and expression. Free Radic Biol Med 2002; 33:337-349.
19. Juarez JC, Betancourt O Jr, Pirie-Shepherd SR, Guan X, Price ML, Shaw DE, et al. Copper binding by tetrathiomolybdate attenuates angiogenesis and tumor cell proliferation through the inhibition of superoxide dismutase 1. Clin Cancer Res 2006; 12:4974-4982.
20. Doñate F, Juarez JC, Burnett ME, Manuia MM, Guan X, Shaw DE, et al. Identification of biomarkers for the antiangiogenic and antitumour activity of the superoxide dismutase 1 (SOD1) inhibitor tetrathiomolybdate (ATN-224). Br J Cancer 2008; 98:776-783.
21. Li JJ, Tang Q, Li Y, Hu BR, Ming ZY, Fu Q, et al. Role of oxidative stress in the apoptosis of hepatocellular carcinoma induced by combination of arsenic trioxide and ascorbic acid. Acta Pharmacol Sin 2006; 27:1078-1084.
22. Mathieu J, Besançon F. Clinically tolerable concentrations of arsenic trioxide induce p53-independent cell death and repress NF-kappa B activation in Ewing sarcoma cells. Int J Cancer 2006; 119:1723-1727.
23. Baysan A, Yel L, Gollapudi S, Su H, Gupta S. Arsenic trioxide induces apoptosis via the mitochondrial pathway by upregulating the expression of Bax and Bim in human B cells. Int J Oncol 2007; 30:313-318.
24. Nagendra SN, Shetty KT, Subhash MN, Guru SC. Role of glutathione reductase system in disulfiram conversion to diethyldithiocarbamate. Life Sci 1991; 49:23-28.
25. Nagendra SN, Shetty KT, Rao KM, Rao BS. Effect of disulfiram administration on rat brain glutathione metabolism. Alcohol 1994; 11:7-10.
26. Cen D, Brayton D, Shandeh B, Meyskens FL Jr, Farmer P. Disulfiram facilitates intracellular Cu uptake and induces apoptosis in human melanoma cells. J Med Chem 2004; 47:6914-6920.
27. Wickström M, Danielsson K, Rickardson L, Gullbo J, Nygren P, Isaksson A, et al. Pharmacological profiling of disulfiram using human tumor cell lines and human tumor cells from patients. Biochem Pharmacol 2007; 73:25-33.
28. Lövborg H, Oberg F, Rickardson L, Gullbo J, Nygren P, Larsson R. Inhibition of proteasome activity, nuclear factor-KappaB translocation and cell survival by the antialcoholism drug disulfiram. Int J Cancer 2006; 118:1577-1580.
29. Chou J. Quantitation of synergism and antagonism of two or more drugs by computerized analysis. In: Chou TC, Rideout DC, editors. Synergism and antagonism in chemotherapy. New York: Academic Press; 1991. pp. 223-244.
30. Quirt I, Verma S, Petrella T, Bak K, Charette M. Temozolomide for the treatment of metastatic melanoma: a systematic review. Oncologist 2007; 12:1114-1123. (Pubitemid 350007023)
31. Griffith OW, Meister A. Potent and specific inhibition of glutathione synthesis by buthionine sulfoximine (S-n-butyl homocysteine sulfoximine). J Biol Chem 1979; 254:7558-7560.
32. Armstrong JS, Steinauer KK, Hornung B, Irish JM, Lecane P, Birrell GW, et al. Role of glutathione depletion and reactive oxygen species generation in apoptotic signaling in a human B lymphoma cell line. Cell Death Differ 2002; 9:252-263.
33. Distler O, Distler JH, Scheid A, Acker T, Hirth A, Rethage J, et al. Uncontrolled expression of vascular endothelial growth factor and its receptors leads to insufficient skin angiogenesis in patients with systemic sclerosis. Circ Res 2002; 95:109-116.
34. Dachs GU, Patterson AV, Firth JD, Ratcliffe PJ, Townsend KM, Stratford IJ, et al. Targeting gene expression to hypoxic tumor cells. Nat Med 1997; 3:515-520.
35. Blancher C, Harris AL. The molecular basis of the hypoxia response pathway: tumour hypoxia as a therapy target. Cancer Metastasis Rev 1998; 17:187-194.
36. Rapisarda A, Uranchimeg B, Scudiero DA, Selby M, Sausville EA, Shoemaker RH, et al. Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. Cancer Res 2002; 62:4316-4324.
37. Berenson JR, Boccia RV, Bashey A, Levine AM, Koc ON, Callahan JA, et al. Phase I study of the [Cu,Zn] speroxide dismutase (SOD1) inhibitor ATN-224 (Bis-choline tetrathiomolybdate) in patients with advanced hematologic malignancies. Blood (ASH Annual Meeting Abstracts) 2006; 108: Abstract 2593.
38. Lowndes SA, Adams A, Timms A, Middleton M, Hayward C, Reich SD, et al. Phase I study of ATN-224 in patients with advanced solid tumors. ASCO Annual Meeting Proceedings Part 1 2006; 24. Abstract 18S.